Glucagon like peptide 1 analogue, Liraglutide, reduces adipose insulin resistance and hepatic de novo lipogenesis in Nonalcoholic Steatohepatitis: Sub-study results of a phase II randomised-control clinical trial

Glucagon like peptide 1 analogue, Liraglutide, reduces adipose insulin resistance and hepatic de novo lipogenesis in Nonalcoholic Steatohepatitis: Sub-study results of a phase II randomised-control clinical trial

Bibliografiska uppgifter
Huvudupphovsmän: Armstrong, M, Hull, D, Guo, K, Barton, D, Hazlehurst, J, Nasiri, M, Gathercole, L, Yu, J, Gaunt, P, Gough, S, Tomlinson, J, Newsome, P
Materialtyp: Conference item
Publicerad: 2013

Liknande verk